# TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

> **NCT00740389** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 18 (actual)

## Conditions studied

- HIV
- AIDS
- Fungal Infection

## Interventions

- **DRUG:** TMC125

## Key facts

- **NCT ID:** NCT00740389
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2011-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740389, "TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00740389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*